Timothy E. Morey
Corporate Officer/Principal bij University of Florida
Profiel
Dr. Timothy E.
Morey, MD, is a Professor at University of Florida and a Principal at Kegonsa Capital Partners LLC.
He is on the Board of Directors at Nanomedex Pharmaceuticals, Inc.
He received his doctorate degree from the University of Florida.
Actieve functies van Timothy E. Morey
| Bedrijven | Functie | Begin |
|---|---|---|
| University of Florida | Corporate Officer/Principal | 25-11-2009 |
Eerdere bekende functies van Timothy E. Morey
| Bedrijven | Functie | Einde |
|---|---|---|
NanoMedex Pharmaceuticals, Inc.
 NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI. | Oprichter | - |
Opleiding van Timothy E. Morey
| University of Florida | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
NanoMedex Pharmaceuticals, Inc.
NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI. | Health Technology |
